XML 66 R43.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaboration and License Agreements - Additional Information (Details) |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Oct. 26, 2021 USD ($) | May 05, 2021 CrisprCas9 | Aug. 31, 2016 USD ($) shares | Aug. 31, 2016 SGD ($) shares | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Research and development costs |  |  |  |  | $ 90,897,000 | $ 63,412,000
Research Collaboration Agreement | Development and Regulatory Approval Milestones |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Reduction of research and development expense resulting from partial reimbursement |  |  |  |  | $ 4,200,000 | 2,300,000
Potential future payments |  |  |  |  | totaling less than mid-twenty million dollars |
Amount paid under the agreement |  |  |  |  | $ 0 |
Amounts owed under the agreement |  |  |  |  | 0 |
Receivable under research cost sharing provision |  |  |  |  | 1,300,000 |
MaxCyte License Agreement | Minimum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | $ 10,000,000 |  |  |  |  |
Net sales milestone payments | 61,900,000 |  |  |  |  |
Annual research license fees and Commercialization license fees | 100,000 |  |  |  |  |
MaxCyte License Agreement | Maximum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Potential milestone payments | 13,000,000 |  |  |  |  |
Net sales milestone payments | 116,800,000 |  |  |  |  |
Annual research license fees and Commercialization license fees | $ 300,000 |  |  |  |  |
NK Cell Products | Research Collaboration Agreement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Number of non-exclusive rights to gene editing targets licenses received | CrisprCas9 |  | 3 |  |  |  |
NK Cell Products | Research Collaboration Agreement | Minimum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Number of non-exclusive rights to gene editing targets | CrisprCas9 |  | 2 |  |  |  |
NUS and St. Jude | License Agreement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Upfront payment |  |  | $ 31,800 | $ 42,750 |  |
Upfront payment, shares issued | shares |  |  | 250,000 | 250,000 |  |
Fair value of common stock issued |  |  | $ 2,500 |  |  |
Annual license maintenance fee |  |  |  | $ 25,000 |  |
Potential milestone payments |  |  |  | $ 5,000,000 |  |
Percentage of licensors royalties |  |  | 2.50% | 2.50% |  |
NUS and St. Jude | License Agreement | Minimum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Percentage of sublicensing income |  |  | 7.50% | 7.50% |  |
NUS and St. Jude | License Agreement | Maximum |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Percentage of sublicensing income |  |  | 20.00% | 20.00% |  |
License agreement term |  |  | 120 months | 120 months |  |
NUS and St. Jude | License Maintenance Fees | License Agreement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Research and development costs |  |  |  |  | $ 37,000 | $ 37,000
NUS and St. Jude | After Year Two of the Agreement | License Agreement |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Annual license maintenance fee |  |  |  | $ 50,000 |  |

X
- Definition Amounts owed under agreement. + References No definition available. + Details
Name: | nktx_AmountsOwedUnderAgreement
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Annual license maintenance fee. + References No definition available. + Details
Name: | nktx_AnnualLicenseMaintenanceFee
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual research license fees and Commercialization license fees. + References No definition available. + Details
Name: | nktx_AnnualResearchLicenseFeesAndCommercializationLicenseFees
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of common stock issued. + References No definition available. + Details
Name: | nktx_FairValueOfCommonStockIssued
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement term. + References No definition available. + Details
Name: | nktx_LicenseAgreementTerm
Namespace Prefix: | nktx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement upfront payment. + References No definition available. + Details
Name: | nktx_LicenseAgreementUpfrontPayment
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Net sales milestone payments. + References No definition available. + Details
Name: | nktx_NetSalesMilestonePayments
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of non exclusive rights to gene editing targets. + References No definition available. + Details
Name: | nktx_NumberOfNonExclusiveRightsToGeneEditingTargets
Namespace Prefix: | nktx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of non exclusive rights to gene editing targets licenses received. + References No definition available. + Details
Name: | nktx_NumberOfNonExclusiveRightsToGeneEditingTargetsLicensesReceived
Namespace Prefix: | nktx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments made under collaborative arrangement. + References No definition available. + Details
Name: | nktx_PaymentsMadeUnderCollaborativeArrangement
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of Licensors royalties. + References No definition available. + Details
Name: | nktx_PercentageOfLicensorsRoyalties
Namespace Prefix: | nktx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sublicensing income. + References No definition available. + Details
Name: | nktx_PercentageOfSublicensingIncome
Namespace Prefix: | nktx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future payments based on achievement of milestones. + References No definition available. + Details
Name: | nktx_PotentialFuturePaymentsBasedOnAchievementOfMilestones
Namespace Prefix: | nktx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | nktx_PotentialMilestonePayments
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Receivable under research cost sharing provision. + References No definition available. + Details
Name: | nktx_ReceivableUnderResearchCostSharingProvision
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Reduction of research and development expense resulting from partial reimbursement. + References No definition available. + Details
Name: | nktx_ReductionOfResearchAndDevelopmentExpenseResultingFromPartialReimbursement
Namespace Prefix: | nktx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock issued during period shares issued upfront payments. + References No definition available. + Details
Name: | nktx_StockIssuedDuringPeriodSharesIssuedUpfrontPayments
Namespace Prefix: | nktx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktx_ResearchCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktx_DevelopmentAndRegulatoryApprovalMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktx_MaxcyteLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nktx_NkCellProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nktx_NationalUniversityOfSingaporeAndStJudeChildrenSResearchHospitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktx_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=nktx_AfterYearTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |